Quarterly Consolidated Statement Of Cash Flows

Kringle Pharma,Inc. - Filing #7290853

Concept 2023-10-01 to
2024-09-30
As at
2024-09-30
2022-10-01 to
2023-09-30
As at
2023-09-30
As at
2022-09-30
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
-816,977,000 JPY
-837,533,000 JPY
Interest and dividends received
10,000 JPY
5,000 JPY
Income taxes paid
-1,491,000 JPY
-1,490,000 JPY
Net cash provided by (used in) operating activities
-661,166,000 JPY
-689,095,000 JPY
Cash flows from investing activities
Net cash provided by (used in) investing activities
-121,363,000 JPY
-120,875,000 JPY
Cash flows from financing activities
Purchase of treasury shares
-31,000 JPY
JPY
Net cash provided by (used in) financing activities
838,233,000 JPY
69,164,000 JPY
Net increase (decrease) in cash and cash equivalents
55,703,000 JPY
-740,806,000 JPY
Cash and cash equivalents
1,816,943,000 JPY
1,761,239,000 JPY
2,502,046,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.